Shire Pharmaceuticals Group plc
Hampshire International Business Park
About Shire Pharmaceuticals Group plcShire traces its history back to 1986, when a small team of entrepreneurs sought out a solution to address on a number of unmet medical needs. Within its first two years of operation, the company had launched a range of supplemental calcium products for patients seeking to treat or prevent osteoporosis. Soon thereafter, innovative drug development programs were under way on behalf of patients facing such challenging conditions as Alzheimer's disease and end-stage renal failure.
By 1992, Shire had embarked on the first of what would be a series of strategic acquisitions -- these were bold ventures that fortified our product lines and underscored the wisdom of a business model focused exclusively on products sold to specialist physicians. After the turn of the millennium, with the acquisition of TKT, we began our focus on rare diseases, something that remains a strategic focus for the company today. The Shire pipeline continues to be sustained by creative acquisitions and innovative licensing deals. Smart commercialization strategies have ensured that the right patients and the right physicians have the information they need to make appropriate choices about treatment options.
In June 2016, Shire completed a combination with Baxalta, creating the world’s leading global biotechnology company focused on serving patients with rare diseases and other highly specialized conditions. With over 22,000 employees across more than 100 countries, Shire’s expanded global reach and best-in-class products offer the potential to help even more patients around the world with significant unmet needs.
FOUNDER: Harry Stratford
CEO: Flemming Ornskov
CFO: Jeffrey Poulton
Please click here for Shire job opportunities..
Please click here for clinical trial information..
Please click here for product information..
Tweets by Shire
432 articles with Shire Pharmaceuticals Group plc
Shire reports 8% pro forma product sales and strong earnings growth resulting in record operating cash flow for full year 2017.
Shire Presentations at EAHAD 2018 Demonstrate Commitment to Studying Outcomes in Patients With Bleeding Disorders
Shire's presence at EAHAD, with five presentations, showcases its heritage in bleeding disorders and dedication to studying hemophilia patient outcomes.
As at January 31, 2018, the Company's issued ordinary share capital comprised 910,039,956 ordinary shares of 5 pence each with voting rights and a further 7,357,283 ordinary shares held in treasury.
Flemming Ornskov, MD, M.P.H., Chief Executive Officer and John Miller, Interim Chief Financial Officer will host the investor and analyst conference call at 9:00 am EST / 14:00 GMT.
Rare disease giant Shire plunked down an undisclosed sum to get its hands on a preclinical autoimmune drug candidate being developed by AB Biosciences.
FDA Grants Approval to Shire for Technology Transfer of CINRYZE Drug Product Manufacturing Process to Vienna, Austria Manufacturing Site
Shire will begin commercial manufacturing of Cinryze drug product in Vienna in the first quarter of 2018.
Shire Continues to Uphold High Standards of Ethics and Transparency With Adoption of Open Access Policy for Publication of Shire-Supported Research
Shire's open access policy, which went into effect on January 2, 2018, was announced today at the 2018 European Meeting of International Society for Medical Publication Professionals (ISMPP) taking place in London, UK, January 23-24.
Shire will have its new CFO in March.
Shire Granted EU Marketing Authorization for ADYNOVI [Antihemophilic Factor (Recombinant), Pegylated] for Adults and Adolescents With Hemophilia A
Marketing Authorization will enable patient access to ADYNOVI throughout Europe.
Shire is splitting into two separate internal business units, Rare Disease Division and Neuroscience Division.
A look at the lucky drugs that have been hailed a breakthrough by the FDA.
Maribavir is a Phase 3 investigational treatment for cytomegalovirus infection and disease in transplant patients resistant or refractory to prior therapy.
The new facility will add about 30 percent more capacity to Shire's internal network.
12/20/2017Takeover whispers boosted long-standing target Shire to the top of the FTSE 100 as the pharma firm's shares rallied on hopes of a mega deal bringing shareholders an early Christmas present.
An experimental treatment to address cognitive impairment in pediatric patients diagnosed with the rare disease known as Hunter syndrome failed a key trial, Shire PLC announced this morning.
12/19/2017The myPKFiT for ADVATE software represents an innovative approach to estimating a patient's PK curve, a key measure for assessing drug exposure over time.
Roche's patent dispute with Shire over the new haemophilia drug Hemlibra has escalated, with Shire filing a new motion in a U.S. court that Roche says aims to stop some patients from getting its medicine.
There are some changes taking place in the C-suites at Shire.
As part of consolidation program, Shire is looking to sell a manufacturing facility in Milford, MA that it gained through its 2015 acquisition of Baxalta.
Sachem Head Capital Management is pushing for that company to break up into small entities in order to increase shareholder value.